Loading...
Loading...
SWTX| Name | Value |
|---|---|
| Revenues | 5.6M |
| Cost of Revenue | 0.9M |
| Gross Profit | 4.7M |
| Operating Expense | 84.0M |
| Operating I/L | -84.0M |
| Other Income/Expense | 4.6M |
| Interest Income | 5.7M |
| Pretax | -79.4M |
| Income Tax Expense | -5.7M |
| Net Income/Loss | -79.4M |
SpringWorks Therapeutics, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing medicines for rare diseases and cancer. The company's lead product candidate, nirogacestat, is in Phase III clinical trial for desmoid tumors, and it is also developing mirdametinib for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors. Additionally, SpringWorks Therapeutics has collaborations and license agreements with leading pharmaceutical companies to develop combination therapies and novel small molecule inhibitors. The company's revenue is generated through the development and commercialization of these innovative medicines for underserved patient populations.
